Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day

MYOMO, INC.

Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.
Manufacturing capacity to reach 250 MyoPros/month with existing plus new space available in July 2025.
Cost-reduction projects targeting ~200 bps gross margin improvement quarterly by end of 2026.
Targets: gross margin 70-72%, EBITDA margin 15-20%, cash flow breakeven at $17-18M quarterly revenue.
Private payer contracts cover 27M+ lives; lead generation recovered from early Q1 2025 challenges.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.